Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer

High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy

(2020) Chunyan Wang et al.   LUNG

Initial platelet-to-lymphocyte count as prognostic factor in limited-stage small cell lung cancer

(2019) Qing Zhang et al.   Biomarkers in Medicine

Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line – Results from the prospective German TLK cohort study

(2019) Claus-Christoph Steffens et al.   LUNG CANCER

The efficacy of amrubicin third‐line chemotherapy in patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective and historical study in a single institute

(2019) Kei Sonehara et al.   Thoracic Cancer

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors

(2019) Meyers et al.   Cancers

Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

(2018) Alessandro Russo et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden

(2018) Salomon Tendler et al.   LUNG CANCER

Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer

(2018) Ryoko Suzuki et al.   RADIOTHERAPY AND ONCOLOGY

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

(2018) Laura Mezquita et al.   JAMA Oncology

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer

(2018) Masayuki Shirasawa et al.   Cancer Management and Research

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

(2017) Corinne Faivre-Finn et al.   LANCET ONCOLOGY

Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer

(2017) Lukas Käsmann et al.   LUNG

What's New in SCLC? A Review

(2017) Bryan Oronsky et al.   NEOPLASIA

Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis

(2016) Xiuxiu Zhang et al.   Cancer Biomarkers

Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer

(2015) Xuan Hong et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer

(2014) M H Kang et al.   BRITISH JOURNAL OF CANCER

Surgical Resection Should Be Considered for Stage I and II Small Cell Carcinoma of the Lung

(2012) Benny Weksler et al.   ANNALS OF THORACIC SURGERY

Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – A retrospective single institution analysis

(2010) Andreas Hermes et al.   RESPIRATORY MEDICINE

Prognostic factors differ by tumor stage for small cell lung cancer

(2009) Nathan R. Foster et al.   CANCER

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

(2009) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY